StockNews.com Downgrades Supernus Pharmaceuticals (NASDAQ:SUPN) to Buy

StockNews.com lowered shares of Supernus Pharmaceuticals (NASDAQ:SUPN) from a strong-buy rating to a buy rating in a research report sent to investors on Thursday morning.

Separately, Cantor Fitzgerald reissued a “neutral” rating and issued a $36.00 price objective on shares of Supernus Pharmaceuticals in a research note on Wednesday.

Supernus Pharmaceuticals Trading Down 0.5 %

Shares of SUPN opened at $31.76 on Thursday. Supernus Pharmaceuticals has a 12 month low of $25.53 and a 12 month high of $40.28. The firm’s 50 day moving average is $37.19 and its 200-day moving average is $35.34. The stock has a market capitalization of $1.75 billion, a PE ratio of 29.68 and a beta of 0.90.

Insider Activity at Supernus Pharmaceuticals

In other Supernus Pharmaceuticals news, SVP Jonathan Rubin sold 927 shares of the firm’s stock in a transaction that occurred on Friday, February 21st. The shares were sold at an average price of $39.15, for a total value of $36,292.05. Following the sale, the senior vice president now owns 7,853 shares in the company, valued at $307,444.95. This trade represents a 10.56 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, VP Padmanabh P. Bhatt sold 9,477 shares of the firm’s stock in a transaction that occurred on Tuesday, February 4th. The shares were sold at an average price of $39.70, for a total transaction of $376,236.90. Following the completion of the sale, the vice president now owns 10,149 shares in the company, valued at $402,915.30. This represents a 48.29 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 11,104 shares of company stock valued at $440,263 over the last three months. 9.30% of the stock is owned by insiders.

Institutional Trading of Supernus Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in the stock. Jefferies Financial Group Inc. acquired a new stake in Supernus Pharmaceuticals in the fourth quarter valued at approximately $890,000. GF Fund Management CO. LTD. acquired a new stake in Supernus Pharmaceuticals in the fourth quarter valued at approximately $42,000. Ashford Capital Management Inc. boosted its position in Supernus Pharmaceuticals by 0.3% in the fourth quarter. Ashford Capital Management Inc. now owns 545,775 shares of the specialty pharmaceutical company’s stock valued at $19,735,000 after buying an additional 1,740 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in Supernus Pharmaceuticals by 24.7% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 100,020 shares of the specialty pharmaceutical company’s stock valued at $3,617,000 after buying an additional 19,824 shares in the last quarter. Finally, Woodline Partners LP boosted its position in Supernus Pharmaceuticals by 124.8% in the fourth quarter. Woodline Partners LP now owns 423,828 shares of the specialty pharmaceutical company’s stock valued at $15,326,000 after buying an additional 235,257 shares in the last quarter.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.